TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-3701
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2 ; volume:8 ; number:1 ; day:28 ; month:11 ; year:2018 ; pages:1-11 ; date:12.2018
Cell & bioscience ; 8, Heft 1 (28.11.2018), 1-11, 12.2018
- Urheber
-
Xu, Caihui
Guo, Yinmou
Liu, Haiyan
Chen, Gongbin
Yan, Yanju
Liu, Teng
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13578-018-0260-0
- URN
-
urn:nbn:de:101:1-2019011401061989142206
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Xu, Caihui
- Guo, Yinmou
- Liu, Haiyan
- Chen, Gongbin
- Yan, Yanju
- Liu, Teng
- SpringerLink (Online service)
Ähnliche Objekte (12)
Long non-coding RNA CIR inhibits chondrogenic differentiation of mesenchymal stem cells by epigenetically suppressing ATOH8 via methyltransferase EZH2
EZH2 facilitates BMI1-dependent hepatocarcinogenesis through epigenetically silencing microRNA-200c
Insulin/Snail1 axis ameliorates fatty liver disease by epigenetically suppressing lipogenesis
LncRNA MSTO2P promotes colorectal cancer progression through epigenetically silencing CDKN1A mediated by EZH2
LncRNA Dlx6os1 Accelerates Diabetic Nephropathy Progression by Epigenetically Repressing SOX6 via Recruiting EZH2
Formation of Cisplatin Adducts with the Epigenetically Relevant Nucleobase 5‐Methylcytosine
EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
EZH2, JMJD3, and UTX epigenetically regulate hepatic plasticity inducing retro-differentiation and proliferation of liver cells
ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells
P38α/JNK signaling restrains erythropoiesis by suppressing Ezh2-mediated epigenetic silencing of Bim
EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations
Ube2v1-mediated ubiquitination and degradation of Sirt1 promotes metastasis of colorectal cancer by epigenetically suppressing autophagy
Long non-coding RNA CIR inhibits chondrogenic differentiation of mesenchymal stem cells by epigenetically suppressing ATOH8 via methyltransferase EZH2
EZH2 facilitates BMI1-dependent hepatocarcinogenesis through epigenetically silencing microRNA-200c
Insulin/Snail1 axis ameliorates fatty liver disease by epigenetically suppressing lipogenesis
LncRNA MSTO2P promotes colorectal cancer progression through epigenetically silencing CDKN1A mediated by EZH2
LncRNA Dlx6os1 Accelerates Diabetic Nephropathy Progression by Epigenetically Repressing SOX6 via Recruiting EZH2
Formation of Cisplatin Adducts with the Epigenetically Relevant Nucleobase 5‐Methylcytosine
EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
EZH2, JMJD3, and UTX epigenetically regulate hepatic plasticity inducing retro-differentiation and proliferation of liver cells
ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells
P38α/JNK signaling restrains erythropoiesis by suppressing Ezh2-mediated epigenetic silencing of Bim
EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations
Ube2v1-mediated ubiquitination and degradation of Sirt1 promotes metastasis of colorectal cancer by epigenetically suppressing autophagy
Long non-coding RNA CIR inhibits chondrogenic differentiation of mesenchymal stem cells by epigenetically suppressing ATOH8 via methyltransferase EZH2
EZH2 facilitates BMI1-dependent hepatocarcinogenesis through epigenetically silencing microRNA-200c
Insulin/Snail1 axis ameliorates fatty liver disease by epigenetically suppressing lipogenesis
LncRNA MSTO2P promotes colorectal cancer progression through epigenetically silencing CDKN1A mediated by EZH2
LncRNA Dlx6os1 Accelerates Diabetic Nephropathy Progression by Epigenetically Repressing SOX6 via Recruiting EZH2
Formation of Cisplatin Adducts with the Epigenetically Relevant Nucleobase 5‐Methylcytosine
EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
EZH2, JMJD3, and UTX epigenetically regulate hepatic plasticity inducing retro-differentiation and proliferation of liver cells
ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells
P38α/JNK signaling restrains erythropoiesis by suppressing Ezh2-mediated epigenetic silencing of Bim
EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations